Zai Lab EPS - Earnings per Share 2016-2022 | ZLAB

Zai Lab eps - earnings per share from 2016 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Zai Lab Annual EPS
2021 $-7.58
2020 $-3.46
2019 $-3.03
2018 $-2.64
2017 $-2.32
2016 $-3.97
2015 $-2.07
Zai Lab Quarterly EPS
2022-03-31 $-0.86
2021-12-31 $-2.17
2021-09-30 $-1.01
2021-06-30 $-1.76
2021-03-31 $-2.64
2020-12-31 $-0.88
2020-09-30 $-0.84
2020-06-30 $0.00
2020-03-31 $-0.66
2019-12-31 $0.00
2019-09-30 $0.00
2019-06-30 $0.00
2018-12-31 $0.00
2017-12-31 $0.00
2017-06-30 $0.00
2016-12-31 $0.00
2015-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.497B $0.144B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.724B 9.84
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.093B 15.93
Biohaven Pharmaceutical Holding (BHVN) United States $9.948B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.434B 0.00
Emergent Biosolutions (EBS) United States $1.592B 6.82
Arcus Biosciences (RCUS) United States $1.327B 33.64
Myovant Sciences (MYOV) United Kingdom $0.961B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.483B 0.00
Gelesis Holdings (GLS) United States $0.357B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.00
SQZ Biotechnologies (SQZ) United States $0.092B 0.00